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a b s t r a c t
Introduction: With the increasing use of immunobiological drugs (IBD), the knowledge about 
their effectiveness and safety has increased. 
Objective: To analyze the immediate infusional reactions (IIR) to intravenous IBD: infliximab 
(IFX), rituximab (RTX), abatacept (ABT) and tocilizumab (TCZ) on the treatment of autoim-
mune diseases. 
Method: 2126 infusions performed in the Infusion Centre - CID in 268 patients were ana-
lyzed. The used drug, its clinical indication, infusion time, and use of premedication were 
determined by the prescribing physician. All intercurrences presented during infusion and/
or during a thirty minutes observation period  were considered as IIR. The approach ad-
opted in IIR followed the protocols of the Infusion Centre - CID. 
Results: Regarding the type of IBD, the infused drugs given were: IFX (1584, 74.5%), TCZ (226, 
10.63%), RTX (185, 8.7%) and ABT (131, 6,16%). IIR were described in 87 procedures (9.4%): 
77 - IFX group and 10 - RTX group. IIR were not described in ABT and TCZ groups. Most were 
considered as mild (n = 5; 41.17%) or moderate (n = 50, 58.81%) reactions; there were no seri-
ous reactions. Regarding to discontinue infusions, 79 (92.9%) were resumed and completed 
successfully. Only six (0.28% of infusions) were not completed because of IIR. 
Conclusion: Despite the differences between the number of procedures per drug, ours is a 
“real life” analysis, where the incidence of IIR was similar to that described in the literature. 
The low incidence of IIR corroborates the safety data, both quantitatively and qualitatively, 
and underscores the importance of specialized medical support during infusion.
© 2014 Elsevier Editora Ltda. All rights reserved.
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Reações infusionais imediatas a agentes imunobiológicos endovenosos 
no tratamento de doenças autoimunes: experiência de 2.126 
procedimentos em um centro de infusão não oncológico
Palavras-chave:
Reações infusionais imediatas
Imunobiológicos
Doenças autoimunes
r e s u m o
Introdução: Com o crescimento do uso de drogas imunobiológicas (IBD) ampliamos o conhe-
cimento sobre sua eficácia e segurança.
Objetivo: Analisar as reações infusionais imediatas (RII) às IBD endovenosas – infliximabe 
(IFX), rituximabe (RTX), abatacepte (ABT) e tocilizumabe (TCZ) – no tratamento de doenças 
autoimunes.
Método: Avaliamos 2.126 infusões feitas no CID (Centro de Infusão) em 268 pacientes. A 
droga usada, a indicação clínica, o tempo de infusão e o uso de pré-medicação foram deter-
minados pelo médico prescritor. Foram consideradas RII todas as intercorrências apresen-
tadas durante a infusão e/ou período observacional de 30 minutos. A conduta adotada nas 
RII seguiu os protocolos do CID.
Resultados: Em relação ao tipo de IBD, as infusões foram distribuídas em: IFX (1.584; 74,5%), 
TCZ (226; 10,63%), RTX (185; 8,7%) e ABT (131; 6,16%). As RII foram descritas em 87 procedi-
mentos (4,09%): 77 no grupo IFX e 10 no grupo RTX. Não foram descritas RII nos grupos de 
ABT e TCZ. A maioria foi considerada leve (n = 5; 41,17%) ou moderada (n = 50; 58,81%) e não 
houve reações graves. Das infusões interrompidas, 79 (92,9%) foram reiniciadas e concluí-
das com êxito. Apenas seis (0,28%) não foram concluídas por causa das RII.
Conclusão: Apesar da diferença entre o número de procedimentos por droga, trata-se de 
uma análise de “vida real”, na qual a incidência de RII foi semelhante à descrita na literatu-
ra. A baixa incidência de RII corrobora os dados de segurança tanto de forma quantitativa 
como qualitativa e ressalta a importância do acompanhamento médico especializado du-
rante a infusão.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction and objectives
With the growing use of immunobiological drugs (IBD) in 
the treatment of various autoimmune diseases, it has been 
possible to increase our knowledge about their effectiveness 
and safety. 
Currently several substances with different mechanisms 
of action and routes of administration are available, and their 
use is becoming increasingly common in specialties such as 
Rheumatology, Dermatology and Gastroenterology.1
Much of the knowledge about immediate infusional reac-
tions (IIR) of intravenous (IV) IBD is based on results of phase 
II and III clinical studies, or on experiences during oncology 
treatment protocols.2,3 It is therefore necessary to deepen 
these studies in patients with autoimmune diseases, as well 
as to apply them in groups of patients in everyday clinical 
practice;. the “real life”. This study aimed to describe the prev-
alence, severity and outcomes of IIR from the use of IV IBD in 
a Non-Oncology Infusion Centre (CID) – a “real life” scenario 
of the application of these drugs in the treatment of different 
autoimmune diseases.
Materials e methods
Sample
A total of 2126 infusions of IBD IV: infliximab (IFX), tocili-
zumab (TCZ), rituximab (RTX) and abatacept (ABT), were 
performed in a total of 268 patients undergoing treatment 
for autoimmune diseases (rheumatoid arthritis, ankylosing 
spondylitis, psoriatic arthritis, inflammatory bowel disease, 
psoriasis, systemic lupus erythematosus, Sjogren's syndrome, 
systemic vasculitis, uveitis, dermatomyositis, pemphigus and 
antiphospholipid antibody syndrome), were evaluated. These 
infusions were held on the premises of the Infusion Centre - 
CID, from October 2006 to November 2011.
The administered drug and its dose, clinical indication, 
infusion time (provided the adherence to the minimum 
infusional time of each drug given in the package insert: 
IFX,4 2 hours; TCZ,5 1 hour; RTX,6 4 hours; ABT,7 30 m) and 
with or without premedication were determined by the at-
tending physician, according to prescriptions and medical 
reports, except for the RTX group, in which pre-infusional 
medication was used in all procedures, which necessarily 
included corticosteroids and anti-histamines PO or IV. The 
premedication used during IFX, TCZ and ABT infusions var-
ied according to the prescription of the attending physician, 
but in all cases consisted of corticosteroids IV and/or anti-
histamines PO or IV.
Regarding the dose of IV IBD, only in RTX group a standard 
dose of 1 g/infusion was used. For the other drugs, the dosage 
established by the prescribing physician was kept. The differ-
ent doses used in groups IFX, TCZ and ABT, as well as the drip 
type used for drug infusion are detailed in Table 1. An infusion 
pump was only used in RTX infusions.
All infusions were performed intravenously and preceded 
by medical evaluation. Vital signs measurements were per-
formed during and at the end of infusional period. 
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Table 2 – Classification of the severity of IIR according to 
NCI and Infusion Centre - CID protocol of intercurrences. 
Adapted from Common Adverse Events Terminology 
Criteria v4.02 (CTCAE).8
Severity of IIR Infusion Centre - 
CID - Intercurrence 
Protocol
Grade Description Procedure adopted 
at the Infusion 
Centre - CID
1 - mild Mild and transient 
response, no indication 
of interruption of the 
infusion; no indication 
of intervention
No need for 
intervention.
2 – mild/
moderate
Indication for therapy or 
discontinuation of the 
infusion, but with no 
immediate response to 
symptomatic treatment 
(e.g., antihistamines, 
NSAIDs, narcotics, IV 
fluids), Prophylactic 
medications indicated 
for ≤ 24 hours
Temporary 
interruption of the 
infusion, use of 
rescue medication, if 
necessary; infusion 
resumed after 
complete resolution 
of symptoms.
3 – moderate Brief or prolonged 
interruption of 
the infusion (e.g., 
no rapid response 
to symptomatic 
medications); 
recurrence of 
symptoms after 
initial improvement: 
hospitalization 
indicated for other 
clinical sequelae
Temporary 
interruption of the 
infusion and use of 
rescue medication; 
infusion resumed 
after complete 
resolution of 
symptoms. Consider 
discontinuation of 
the procedure.
4 – severe Life-threatening 
consequences; urgent 
intervention indicated
Interruption of the 
infusion and use of 
rescue medication 
and hemodynamic 
support. 
Discontinuation of 
the procedure.
5 – severe Death Death
No data on the use of concomitant drugs, disease activity 
indexes or treatment failure were collected.
Immediate reactions
For the present study, IIR were considered as the intercurrenc-
es, symptomatic or not, present during the infusion and/or 
subsequent observational period of 30 minutes. These IIR were 
classified according to the type of event, severity and time of 
event after the start of infusion (Table 2). To facilitate the reac-
tion classification, these were grouped according to systems, 
adopting the following division: angioedematous, cutaneous, 
gastrointestinal, hemodynamic, musculoskeletal, neurologi-
cal, respiratory or mixed (when there was multisystemic in-
volvement). To assess the severity of IIR, the National Cancer 
Institute event severity scale8 was used (Table 2). The approach 
adopted in IIR followed the protocols for intercurrences of the 
Infusion Centre - CID, dividing cases regarding the use or lack 
of rescue medication, with or without temporary interruption 
of the infusion and/or cessation of infusion (Table 2).
Statistical analysis
Data was stored using a Microsoft Access 2007 database and 
analyzed with Prism 4.0 software. The results were presented 
in absolute percentage (%), considering the total number of 
infusions; and relative percentage (%), considering the sub-
groups analyzed (type of drug and IIR). Due to the retrospec-
tive nature of the analysis, informed consents were not ob-
tained, but patients' data were protected by numeric codes.
Results
IBD infusions
During the period between October 2006 and November 
2011, a total number of 268 patients with autoimmune dis-
eases were treated with IV IBD at the Infusion Centre, total-
ling 2126 infusions performed. Regarding the type of drug 
used, the infusions were distributed as follows, in order of 
prevalence: IFX, n = 1584 (74.50%); TCZ, n = 226 (10.63%); RTX, 
Table 1 – Distribution of IIR by drug × number of drug 
infusions and elapsed infusion time.
Infliximab
1584
Reactions = 77
n (%)
Rituximab
185
Reactions = 10
n (%)
Total
2126
87
n (%)
Number of infusions 
1st 13 (16.88) 6 (60) 19 (21.83)
2nd to 4th 23 (29.87) 4 (40) 27 (31.03)
5th to 8th 18 (23.37) - 18 (9.19)
9th to 16th 16 (20.77) - 16 (18.39)
After 16th 7 (9.09) - 7 (8.04)
Infusion Time
< 30 min. 21 (27.27) - 21 (26.25) 
30-60 min. 26 (33.76) 2 (20) 28 (35)
60-120 min. 16 (20.77) 3 (30 19 (22.5)
> 120 min. 5 (6.49) 1 (10) 6 (6.25)
NI 9 (11.68) 4 (40) 13 (17.56)
Outcome
Resumed after 
initial measures, 
and finalized 
69 (89.61) 10 79 (90.8)
Suspension of 
procedure after 
initial measures
4 (5.19) 0 4 (4.59)
New IIR after 
initial steps - 
 successful 
completion 
2 (2.59) 0 2 (2.29)
New IIR after 
initial steps - 
suspension of 
procedure
2 (2.59) 0 2 (2.29)
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n = 185 (8.7%); and ABT, n = 131 (6.16%) (Fig. 1). The distribution 
of patients by drug and means of infusions performed in each 
group are presented as follows: IFX = 168 (62.68%) patients 
with a mean of 9.42 infusions/patient (1-32); RTX = 59 (22.01%) 
patients with a mean of 3.13 infusions/patient (1-12); TCZ = 26 
(9.70%) patients with a mean of 8.60 infusions/patient (1-23); 
and ABT = 15 (5.59%) patients with a mean of 8.70 infusions/
patient (1-39).
It is important to note that, considering the characteris-
tics of the study, a single patient may have been subjected to 
more than one type of treatment. Regarding the distribution 
of the registered diagnosis, the most frequent diagnosis was 
rheumatoid arthritis, n = 805 (37.86%), followed by infl amma-
tory bowel disease, n = 416 (19.56%), ankylosing spondylitis, 
n = 376 (17.68%), psoriasis, n = 237 (11,14%), psoriatic arthri-
tis, n = 185 (8.7%), and others (systemic lupus erythematosus, 
Sjogren's syndrome, systemic vasculitis, uveitis, dermatomy-
ositis, pemphigus and antiphospholipid antibody syndrome), 
n = 107 (5.03%). All RTX infusions were preceded by pre-medi-
cation, also used in 530 IFX infusions (33.45%), 1 TCZ infusion 
(0.44%) and 1 ABT infusion (0.76%). As to the dose used, 925 
IFX infusions (58.39%) doses applied were between 3 and 5 
mg/kg, 582 infusions (36.74%) with doses > 5 mg/kg and 77 
infusions (4.86%) with doses < 3 mg/kg. In TCZ group, doses ≤ 
8 mg/kg were used in 143 procedures (63.27%); in 83 infusions 
(36.72%) doses > 8 mg/kg were used. For the ABT group, the 
most widely used dose was 750 mg/infusion, totalling 99 infu-
sions (75.57%), followed by 500 mg, with 22 infusions (16.79%) 
and 250 mg, with 10 infusions (7.63%).
Immediate infusion reactions (IIR) 
Of 2126 infusions, IIR were documented in 87 procedures 
(4.09% of total infusions), with 77 events in the IFX group 
(88.50% of total reactions and 4.86% of IFX infusions) and 10 
in the RTX group (11.49% of total reactions and 5.40% of RTX 
infusions). In groups ABT and TCZ, IIR were not described (Fig. 
1, Table 3).
Regarding severity, IIR classifi ed as moderate were the 
most frequent, reported in 50 (57.47%) infusions; followed by 
mild IIR, occurring in 37 procedures (42.52%) (Table 3). No seri-
ous reaction was reported. 
In terms of clinical presentation, the most common reac-
tions were purely cutaneous (rash, itching, redness, urticari-
form lesions), described in 21 IIR (24.13%) cases, followed by 
19 mixed (multisystemic) (21.83%), 17 hemodynamic (tachy-
cardia, changes in blood pressure) (19.54%), 9 angioedema-
tous (10.34%), 7 gastrointestinal (nausea, vomiting, abdominal 
pain) (8.04%), 5 respiratory (bronchospasm, dyspnea, coughing) 
(5.74%), 5 musculoskeletal (low back pain, arthralgia, myalgia) 
(5.74%), and 3 neurological (headache, drowsiness, confusion) 
(3.44%) reactions (Table 3). In the present study, the relation be-
tween IIR and underlying disease was not addressed.
Regarding post-IIR outcomes in 60 cases of IIR (68.96% of 
total IIR), the drip was discontinued as an initial measure, and 
in 72 cases (82.75%) the use of rescue medication (antihista-
mines, corticosteroids, analgesics, adrenaline) was required 
(Table 3). Of the IFX related IIR, 36 (46.75%) occurred until the 
fourth infusion, and 54 (70.12%) until the eighth; in the major-
ity of the cases, 47 (61.03%), IIR occurred within the fi rst hour 
of the procedure (Table 1). Regarding infusions of RTX, the 10 
IIR cases reported occurred until the fourth infusion of the 
drug, and eight (80%) were reported at the fi rst infusion of the 
application cycle (D0) and 2 (20%) during the second infusion 
(D15). Importantly, the two cases of IIR in D15 occurred in pa-
tients who had already suffered IIR in D0.
Regarding the dose used, most of the IFX related IIR oc-
curred at doses of 3 mg/kg and 5 mg/kg (50 - 64.93%), followed 
by doses > 5 mg/kg (26 - 33.76%) and < 3 mg/kg (1 - 1.29%).
In the present study, the use of premedication was de-
termined by the prescribing physician. The preparation was 
Fig. 1 – Total and percentage of infusions and IIR by drug.
Table 3 – Classifi cation of IIR by drug, severity, clinical 
presentation and behaviour.
Infl iximab
1584
n (%)
Rituximab
185
n (%)
Total
2126
n (%)
Immediate infusional reaction (IIR)
Yes 77 (4.86) 10 (5.40) 87 (4.09)
No 1507 (95.14) 175 (95.60) 2039 (95.91)
Severity
Mild 33 (42.87) 4 (40) 37 (42.52)
Moderate 44 (57.13) 6 (60) 50 (57.47)
Severe - - -
Reaction type
Angioedema 6 (7.79) 3 (30) 9 (10.34)
Purely cutaneous 19 (24.67) 2 (20) 21 (24.13)
Purely 
gastrointestinal
5 (6.49) 2 (20) 7 (8.04)
Purely neurological 1 (1.29) 2 (20) 3 (3.44)
Purely 
musculoskeletal 
4 (5.19) 1 (10) 5 (5.74)
Purely respiratory 5 (6.4) - 5 (5.74)
Purely 
hemodynamic 
17 (22.07) - 17 (19.54)
Multisystemic 19 (24.67) - 19 (21.83)
Other 1 (1.29) - 1 (1.14)
Infusion interruption
Yes 56 (72.72) 4 (40) 60 (68.96)
No 21 (27.27) 6 (60) 27 (31.03)
Rescue medicationa
Yes 65 (84.41) 7 (70) 72 (82.75)
No 12 (15.58) 3 (30) 15 (17.24)
a Antihistamines, corticosteroids, analgesics, adrenaline.
2126
(100)
total IFX RTX TCZ ABT
1584
(74.5)
N total (%)
IIR (%)
77
(4.86)
185
(8.7)
226
(10.63) 131(6.16)0 0
10
(5.4)
87
(4.09)
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prescribed in 33.72% of infusions, and in 52.87% of IIR cases, 
patients were pre-medicated. Of the six procedures in which 
the infusion could not be completed due to IIR, 3 ( 50%) were 
preceded by premedication.
Of all IIR observed, 79 (90.8%) cases were solved using ini-
tial manoeuvres (interruption of the infusion and/or use of 
rescue medication) and the procedure was successfully con-
cluded, with no further intercurrences. In two IFX infusions, 
there was no recurrence of reactive symptoms after initial 
measures, even after required further intervention, which re-
sulted in a successful procedure. In 6 infusions, all from the 
IFX group (7.79% of IIR cases with IFX use and 0.37% of total 
IFX infusion), it was not possible to complete the procedure 
due to the severity or non-resolution of the reactive picture, 
and the infusion was discontinued. All IIR related to RTX were 
reversed and the procedure was completed successfully. As 
an overall result, of the 2126 procedures, only 6 (0.28%) were 
not completed due to IIR.
Discussion
General reactions
Essentially, the infusional reactions are classified in allergic 
(IgE-mediated or of hypersensitivity type I) and non-allergic 
(non-IgE, generally attributed to cytokine release) reactions.9,10 
The majority of infusional reactions related to the infusion 
of monoclonal antibodies pertain to the non-allergic type,11 
but in practice, as the symptoms are very similar, it is dif-
ficult to classify clearly the nature of the reaction, especially 
for autoimmune diseases, which exhibit differentiated patho-
physiological patterns in relation to neoplastic diseases.3 In 
practice, we found that the reactions mediated by the release 
of cytokines, in contrast to those that are mediated by IgE, 
usually resolved with temporary drip suspension and by ad-
ministration of antihistamines; these procedures allowed to 
return to infusion.
Acute reactions to the infusions of monoclonal antibod-
ies are described mostly as mild to moderate [levels 1 and 2, 
according to the classification published by the National Can-
cer Institute (Table 2)], and the incidence of severe reactions 
is small.11-14 In studies using monoclonal antibodies to treat 
cancer, the reactions are described as more frequent during 
the first infusions, and generally managed successfully after 
a temporary reduction or cessation of infusion and the use of 
an appropriate rescue medication. Most patients tolerate well 
the subsequent infusions with the use of premedication.6,15,16 
The results of this study are in line with literature data, since 
most of the observed reactions allowed resuming the infusion 
after initial measures and occurred more often in the initial 
procedures.
One added obstacle in the analysis of comparative stud-
ies is the lack of standardization of nomenclature and of the 
reaction classification of the series, since the designation “in-
fusional reaction” can be found as “allergic reaction”, “acute 
infusional reaction”, “immediate infusional reaction” and 
other terms, generating a possible bias in the interpretation 
of results. In our analysis, considering that all intercurrences 
were classified as IIR, without distinction as to whether or not 
allergic in nature, the results should be interpreted consider-
ing this broader and less specific concept. It is also necessary 
to emphasize that the overall percentages of IIR observed in 
our study may also have been influenced by the pre-medical 
consultation conducted by medical staff of the Infusion Cen-
tre - CID before every infusion, with the main goal of an early 
detection of absolute contraindications prior to the infusion.
Infliximab
IFX is a chimeric (murine-human) monoclonal antibody that 
binds to TNF (tumour necrosis factor), used successfully for 
the control of several autoimmune diseases.1 Among the IV 
IBD evaluated in this study, IFX is the one that has most indi-
cations in the package insert (i.e., rheumatoid arthritis, pso-
riatic arthritis, ankylosing spondylitis, inflammatory bowel 
disease and psoriasis). Since the recommended dosages are 
different for each disease indicated (from 3 to 10 mg/kg/infu-
sion),4 it was necessary to divide the analyzed procedures by 
dose/kg body weight (Table 1).
In a study that compared percentage of discontinuation 
of IFX, etanercept and adalimumab (two other IBD acting on 
TNF, but whose route of administration is subcutaneous), the 
proportion of discontinuations caused by IIR in IFX users was 
23.9%, above the average of the other anti-TNF (16%) and of 
each drug considered individually.17 Possibly because IFX is 
the only anti-TNF agent for IV use available in Brazil, it is the 
drug most related to IIR occurrence in its group. In the lit-
erature, the risk of IIR in IFX users ranges from 0.8% to 8.8% 
by infusion.18-24 In most cases, the IIR are considered mild or 
moderate. Reports describe a frequency of severe reactions 
around 0.5%, and only 2% of patients discontinued the treat-
ment due to infusional reaction.
In patients with Crohn's disease, the reported frequency of 
IIR is 4%-5%, half of which occur until the third infusion (25% 
until the second infusion).25 These values  are closer to those 
observed in our study (4.86%), which included patients with 
different pathologies.
We emphasize that from the procedures analyzed at the 
Infusion Centre - CID, in 21 cases of IIR (27.27%) there was no 
need to interrupt the drip, and in two cases even after a recur-
rent reactive manifestation, it was possible to complete the 
procedure. Only in 6 procedures (7.79% of IIR and 0.37% of all 
infusions of IFX performed) the infusion was not completed 
when it became imperative to discontinue the medication.
The symptoms most frequently described in IIR are head-
ache, dizziness, nausea, rash and pruritus.21,23,24,26 In our study 
a greater relative proportion of hemodynamic changes (hypo- 
or hypertension, tachycardia) was noted, being second in fre-
quency only for cutaneous reactions.
Despite the high frequency of reactions described in the 
literature, and despite some studies that encourage the use 
of premedication in IFX infusions, most of the studies with 
an adequate design do not recommend the use of antihista-
mines or steroids in preparation for infusion in patients naïve 
to transfusional reactions.21,27,28 Regarding the use of premedi-
cation, in 52.87% of cases of IIR premedication was used sug-
gesting that the use of this strategy did not help avoid the 
occurrence of IIR. We emphasize that in some premedication 
cases its use occurred in patients who had previously suffered 
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of IIR, which determines a bias in data analysis. However, we 
emphasize the low frequency of IIR among patients not pre-
medicated (5%), which agrees with the literature and suggests 
that the routine use of premedication is not justified in pa-
tients naïve to previous reactions. Likewise, and even in face 
of the small number of events, the use of the drug preparation 
apparently did not change the IIR outcome, since there was 
no difference for this criterion among the suspended proce-
dures due to IIR. 
Tocilizumab
TCZ is a recombinant humanized monoclonal antibody that 
blocks interleukin-6 receptor that plays a fundamental role 
in the pathophysiology of rheumatoid arthritis. The reported 
frequency of infusional reactions in the literature is around 
7%. The most common symptoms are transient elevation of 
blood pressure, redness at the site of venipuncture, head-
ache, nausea and rashes.29,30 Usually, IIR are mild and tran-
sient, allowing the treatment maintenance. The absence of 
IIR related to TCZ in this study should be interpreted with 
caution, due to the small number of procedures performed, 
226, which accounted for only 10.63% of all procedures. We 
believe that the results obtained in our study favour the in-
fusional safety of TCZ.
Rituximab
RTX is a chimeric (murine-human) anti-CD20 monoclonal 
antibody originally used for the treatment of non-Hodgkin 
lymphoma protocols, and is also approved for the treatment 
of rheumatoid arthritis.6 In other autoimmune diseases such 
as systemic lupus erythematosus, dermatomyositis and some 
systemic vasculitides. RTX has shown efficacy and presents 
itself as a good off-label therapeutic option. Compared to 
studies of non-Hodgkin lymphoma and leukemias, diseaser 
where RTX is commonly used for extended amounts of time, 
the knowledge about the use of this drug for autoimmune dis-
eases is still limited.18 Perhaps this is one reason to explain the 
large discrepancy between data about RTX infusional safety.
As determined in previous studies and recommendations 
of the manufacturer,6 infusions of RTX must be preceded by 
some drug preparation (antihistamines, corticosteroids and 
acetaminophen). This protocol, developed for the treatment 
of lymphoma, is also adopted in the care of patients with 
autoimmune diseases, and has been used in infusions per-
formed at the Infusion Centre - CID.31,32 
Studies show that the incidence of IIR related to RTX use 
can be greater than 70%, but there is evidence that this num-
ber may vary according to the indicated disease, and the reac-
tions are more frequent in the treatment of neoplasms (12% 
in systemic vasculitis, 27% in rheumatoid arthritis and 77% 
in non-Hodgkin lymphoma), for unknown reasons.33 A study 
that analyzed the safety of RTX only for autoimmune diseases 
in 370 patients showed a much lower incidence of IIR (around 
18%), and only 2.4% of treatment discontinuations for severe 
reaction were required. When a secondary analysis was tak-
en, it was found that the risk of reaction per patient did not 
exceed 2%, and there was no statistically significant differ-
ence between the conditions.35
Similar to anti-TNF reactions, the RTX reactions are more 
common during the initial infusions, and occur most fre-
quently within the first two hours of infusion. The proportion 
of IIR dropped by half from the first to the fourth infusion.12,34 
The most common symptoms reported are urticaria, hypo-
tension, angioedema, hypoxia and bronchospasm,  but there 
are also reports of respiratory failure, myocardial infarction, 
cardiogenic shock and severe anaphylaxis.28
As severity, most IIR are of mild to moderate intensity. The 
literature describes around 10% of severe reactions, in rare 
cases leading to death. Certain information of particular in-
terest is that 80% of cases of death related to the infusion of 
RTX occurred at the first round of infusion of the drug.34 In 
our series, the incidence of IIR related to RTX (in 69.72% of 
cases with indication of rheumatoid arthritis treatment) was 
much lower (5.40%), however with a similar pattern to that 
described in the literature. All IIR were considered of mild or 
moderate intensity (no severe reactions in this series), and oc-
curred until the second infusion, 60% of them during the first 
procedure. Despite the reactions presented, all 185 infusions 
of RTX held at the Infusion Centre - CID in the study period 
were completed successfully. During no procedure the dis-
continuation of the infusion due to IIR was needed.
Abatacept
ABT is a fusion protein that blocks and modulates a key co-
stimulatory signal, promoting downregulation of T cells.7 The 
condition most commonly used for are rheumatoid arthri-
tis36,37 and juvenile idiopathic arthritis.38
The frequency of IIR assigned to ABT use in the literature 
is about 9%.39 Specific studies in juvenile idiopathic arthritis 
show percentages around 4%.38 A systematic review describes 
that the rate of discontinuation of ABT because of serious 
adverse events (including severe anaphylaxis) is significant-
ly lower than that of IFX.39 A subgroup analysis, however, 
pointed out that the frequency of adverse events is higher 
in patients with chronic obstructive pulmonary disease and 
diabetes mellitus. Considering that it was not the aim of our 
study to evaluate the relationship of IIR with comorbidities, 
it was not possible to attribute the absence of IIR to the use 
of ABT due to patient characteristics; however, it should be 
emphasized that the existence of obstructive lung disease is 
a  contraindication related to the use of ABT.
Regarding the absence of IIR in the 131 infusions (6.16% of 
infusions) of ABT in this study, the same comments for the 
TCZ group and the expectation of equally promising results 
in relation to the infusional safety profile of this drug are per-
tinent.
We recognize that the main limitation of the combined 
data analysis in our study was the discrepancy among the 
number of IFX infusions, when compared to the other three 
drugs. Some conditions justify this finding:
1) The time span of these drugs in the Brazilian market for 
non-oncological use: Infusions performed  from October 
2006 on were evaluated, when IFX was the only available 
drug in Brazil. The first infusion of the other drugs at the 
Infusion Centre - CID occurred in September 2007 (ABT), 
October 2007 (RTX) and September 2009 (TCZ).
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2) Number of indications in the package insert: IFX has five 
indications: rheumatoid arthritis, ankylosing spondylitis, 
psoriatic arthritis, Crohn's disease, ulcerative colitis and 
psoriasis, while other drugs have only one indication: 
rheumatoid arthritis.
3) Posologic schedule (frequency of infusion): IFX: infusions 
every 6-8 weeks, with plus 3 infusions/year in the case of 
induction therapy; RTX: maximum of 4 infusions/year (2 
infusions, twice a year); TCZ: infusions every 4 weeks; and 
ABT: infusions every 4 weeks, plus one infusion/year in 
case of induction therapy.
Thus, the presented results cannot be interpreted in a 
comparative manner between different drugs, but are signifi-
cantly useful to reflect the practical treatment routine of au-
toimmune diseases with IV IBD.
Conclusions
Despite a heterogeneous distribution of the number of proce-
dures for these drugs, we believe that the results reflect the 
analysis of a “real life” sample, where the frequency of IIR was 
not higher than that described in the literature. The form of 
presentation, behaviour, severity and outcomes were similar 
to those described in different series.
We emphasize that the low prevalence of IIR corroborates 
security data, both quantitatively and qualitatively, of the 
various IV IBD. However, we must emphasize that, despite 
the expansion of the experience with the use of these drugs, 
a specialized medical monitoring is still considered essen-
tial during infusion, either in the immediate handling of the 
event, as for the decision of infusion resuming.
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